ASH 2025 | Key highlights in lymphoma and CLL
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Me...
22 Des 20257min
ASH 2025 | Latest updates from the phase I NX-5948-301 trial of bexobrutideg in patients with R/R CLL
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Alexey Danilov, City of Hope Comprehensi...
18 Des 20254min
What do the clinical data tell us about fixed-duration ibrutinib + venetoclax for patients with CLL?
The Lymphoma Hub was pleased to speak to Susan O’Brien, Chao Family Comprehensive Cancer Center, University of California, Irvine, US. We asked, What do the clinical data tell us about fixed-duration ...
17 Des 20257min
ASH 2025 | EPCORE FL-1 phase III primary results: Epcoritamab with rituximab + lenalidomide (R2) vs R2 alone for R/R FL
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Lorenzo Falchi, Memorial Sloan Kettering...
11 Des 20256min
ASH 2025 | 3-year follow-up results from the STARGLO trial of Glofit-GemOx vs R-GemOx in R/R DLBCL
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Haifaa Abdulhaq, University of Californi...
10 Des 20254min
Glofit-GemOx vs R-GemOx in patients with R/R DLBCL: Results from the STARGLO trial
During the Lymphoma Hub Steering Committee Meeting on October 6, 2025, key opinion leaders met to discuss the results from the phase III STARGLO trial (NCT04408638) of glofitamab (Glofit) + gemcitabin...
5 Des 202536min
What factors influence BTKi + BCL-2i treatment selection for patients with CLL?
The Lymphoma Hub was pleased to speak to Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, what factors influence Bruton’s tyrosine kinase inhibitor (BTKi) + B-cell lym...
5 Nov 20257min
